Glancy Prongay & Murray LLP Commences Investigation on Behalf of Teva Pharmaceuticals Investors Concerning Recent Revelations...
04 Novembre 2016 - 12:16AM
Business Wire
Glancy Prongay & Murray LLP (“GPM”) announces an
investigation on behalf of Teva Pharmaceuticals (“Teva” or the
“Company”) (NYSE: TEVA) investors concerning recent reports that
the Company has unlawfully colluded with other pharmaceutical
companies to fix generic drug prices.
According to news reports, United States prosecutors may file
criminal charges against Teva by the end of 2016 for suspected
price collusion.
Bloomberg News has reported that the “antitrust investigation by
the Justice Department, begun about two years ago, now spans more
than a dozen companies and about two dozen drugs, according to
people familiar with the matter. The grand jury probe is
examining whether some executives agreed with one another to raise
prices, and the first charges could emerge by the end of the year,
they said.”
The companies identified as targets or relevant parties in the
United States investigation include Mylan NV, Teva Pharmaceutical
Industries Ltd, Allergan Plc, Lannett Co., Impax Laboratories Inc.,
Sun Pharmaceutical Industries Ltd., Mayne Pharma Group Ltd., Endo
International Plc and Taro Pharmaceutical Industries Ltd.
On this news, Teva stock fell $4.13 per share, or nearly 10%, to
close at $39.20 per share on November 3, 2016.
If you purchased Teva securities, have information or would like
to learn more about these claims, or have any questions concerning
this announcement or your rights or interests with respect to these
matters, please contact Lesley Portnoy, Esquire, of GPM, 1925
Century Park East, Suite 2100, Los Angeles, California 90067, at
310-201-9150, Toll-Free at 888-773-9224, by email to
shareholders@glancylaw.com, or visit our website at
http://www.glancylaw.com. If you inquire by email please include
your mailing address, telephone number and number of shares
purchased.
This press release may be considered Attorney Advertising in
some jurisdictions under the applicable law and ethical rules.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20161103006905/en/
Glancy Prongay & Murray LLP, Los Angeles/New YorkLesley
Portnoy, 310-201-9150 or
888-773-9224shareholders@glancylaw.comwww.glancylaw.com
Teva Pharmaceutical Indu... (NYSE:TEVA)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Teva Pharmaceutical Indu... (NYSE:TEVA)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024